Literature DB >> 21877428

The madness of King George III: a psychiatric re-assessment.

Timothy J Peters1, Allan Beveridge.   

Abstract

This research, based on a study of King George III's medical records and of contemporary diaries of his courtiers and equerries, further confirms the considerable doubt on the claim of Richard Hunter and Ida Macalpine that the King suffered from recurrent attacks of acute porphyria.The present study examines the above records from a psychiatric viewpoint, together with some additional reports, to re-assess the nature of the King's maladies. It concludes that he suffered from recurrent mania (four episodes), with chronic mania and possibly a degree of fatuity during the last decade of his life.This is in agreement with previous reports that he suffered from manic-depressive psychosis.

Entities:  

Mesh:

Year:  2010        PMID: 21877428     DOI: 10.1177/0957154X09343825

Source DB:  PubMed          Journal:  Hist Psychiatry        ISSN: 0957-154X


  3 in total

1.  Gene expression imputation across multiple brain regions provides insights into schizophrenia risk.

Authors:  Laura M Huckins; Amanda Dobbyn; Douglas M Ruderfer; Gabriel Hoffman; Weiqing Wang; Antonio F Pardiñas; Veera M Rajagopal; Thomas D Als; Hoang T Nguyen; Kiran Girdhar; James Boocock; Panos Roussos; Menachem Fromer; Robin Kramer; Enrico Domenici; Eric R Gamazon; Shaun Purcell; Ditte Demontis; Anders D Børglum; James T R Walters; Michael C O'Donovan; Patrick Sullivan; Michael J Owen; Bernie Devlin; Solveig K Sieberts; Nancy J Cox; Hae Kyung Im; Pamela Sklar; Eli A Stahl
Journal:  Nat Genet       Date:  2019-03-25       Impact factor: 38.330

2.  Multiple sclerosis or neuromyelitis optica? Re-evaluating an 18th-century illness using 21st-century software.

Authors:  Peter Garrard; Timothy J Peters
Journal:  JRSM Short Rep       Date:  2012-01-12

3.  The acute mania of King George III: A computational linguistic analysis.

Authors:  Vassiliki Rentoumi; Timothy Peters; Jonathan Conlin; Peter Garrard
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.